Nanotherapeutics, Inc., an Alachua, Fla.-based integrated biopharmaceutical company with a focus on advanced development and manufacturing, secured a $30m loan facility from Hercules Technology Growth Capital, Inc. (NYSE:HTGC).
The funds will support the company’s efforts to expand its manufacturing infrastructure.
Established in 1999, Nanotherapeutics focuses on developing and cGMP manufacturing pre-clinical and clinical stage biopharmaceutical products.
Products under development include biodefense medical countermeasures, CNS, wound healing, addiction and pain, oncology, anti-infectives, vaccines and orthopedics.
The company has one FDA cleared injectable biologic, NanoFUSE® DBM, used by orthopedic surgeons as bone graft filler. the Company employs several proprietary platform technologies to manipulate and enhance the properties of drug candidates.